

Algorae Pharmaceuticals Partners with Peter MacCallum Cancer Centre for AI-Driven Drug Synergy Screening

Highlights:

- Algorae Pharmaceuticals partners with the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre to validate AI-predicted drug interactions in oncology.
 - The study will focus on 24 AI-generated drug candidates, screened for synergy in four cancer cell lines.
 - The project is expected to generate key preclinical data within six months, accelerating the Company's pipeline development.
-

Melbourne, Australia – 8 May 2025: Algorae Pharmaceuticals Limited (ASX: 1AI) ('Algorae' or 'the Company'), an AI-enabled drug discovery and development company, is pleased to announce that it has entered into an agreement with the Victorian Centre for Functional Genomics ('VCFG') at Peter MacCallum Cancer Centre ('Peter Mac') to validate AI-predicted drug synergies through high-throughput screening.

The study will evaluate 24 drug candidates (21 wholly AI-generated) using VCFG's advanced screening platform, which includes proprietary high-throughput technologies and synergy assessment methodologies. The collaboration is designed to confirm the efficacy of drug combinations across four distinct cancer cell lines, including glioblastoma, pancreatic ductal adenocarcinoma, invasive breast carcinoma and prostate carcinoma.

Strategic Importance to Algorae's AI-Driven Drug Discovery Model

The partnership with VCFG is an important step in validating Algorae's AI-driven approach to drug discovery. The Algorae Operating System ('AlgoraeOS'), developed in collaboration with UNSW AI Institute and supported by CSIRO funding, has predicted these novel drug interactions. Now, this preclinical screening will empirically test the AlgoraeOS predictions and provide essential data to support regulatory and commercial pathways.

"This agreement with Peter Mac marks a significant milestone for Algorae," said David Hainsworth, Executive Chairman of Algorae Pharmaceuticals. "By leveraging Artificial Intelligence to predict synergistic drug interactions we are endeavouring to accelerate the drug discovery process and expand our pipeline. We're excited to collaborate with a premier cancer research institution to validate our findings."

Study Design and Timeline

The screening process, performed in collaboration with VCFG at Peter Mac, will include:

- Optimising cell growth conditions for high-throughput drug screening.
- Generating single-agent dose-response curves across four cancer cell lines.
- Conducting synergy screens using selected dose ranges.
- Imaging and quantifying treatment effects using advanced microscopy and analytics.

Data analysis will be completed within three weeks of each screen run, with the full dataset expected to be completed within six months. Key decision points will be integrated into the study to ensure data quality and optimise further testing.

Commercial and Development Implications

Successful validation of these AI-predicted drug combinations could significantly de-risk their further development. Positive outcomes from the Peter Mac collaboration may support:

- Internal advancement of selected candidates towards clinical studies.
- Out-licensing or partnership opportunities with major pharmaceutical companies.
- Expansion of the AI-driven discovery pipeline into additional therapeutic areas.

Peter MacCallum Cancer Centre

Peter MacCallum Cancer Centre is a world-leading cancer research, education and treatment centre and Australia's only public health service solely dedicated to caring for people affected by cancer. The Victorian Centre for Functional Genomics was established over 16 years ago and is an internationally recognised technology platform (co-supported by Phenomics Australia, a National Collaborative Research Infrastructure Strategy consortia) that enables advanced high throughput screens using gene and drug targeting strategies coupled with innovative image analytics.

Peter Mac currently treats more than 47,000 patients every year, combining care and compassion with the latest research to deliver best possible treatments, care and outcomes for patients. This care is matched with world-class facilities within the Parkville Biomedical Precinct and at six additional metropolitan and regional campuses.

<https://www.petermac.org>

This announcement has been approved by the Board of Directors of Algorae Pharmaceuticals Limited.

End

For more information, please visit www.algoraepharma.com

Corporate and Media Enquiries

Mr Brad Dilkes - Director

P: +61 422 180 317

E: brad@algoraepharma.com

About Algorae Pharmaceuticals

Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical development company focused on discovering and developing novel treatments for unmet medical needs. The Company's proprietary AI platform, AlgoraeOS, utilises machine learning and deep neural networks to identify synergistic drug combinations with the potential to transform patient outcomes. Algorae collaborates with leading research institutions and pharmaceutical partners to accelerate the translation of AI-predicted therapies into the clinic.

Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.